Inceptive is a Palo Alto, California-based biotechnology that uses AI to design unique mRNA sequences that can be rapidly created and tested in the lab.
Inceptive is a Palo Alto, California-based biotechnology that uses AI to design unique mRNA sequences that can be rapidly created and tested in the lab.
Inceptive is a Palo Alto, California-based biotechnology that uses AI to design unique mRNA sequences that can be rapidly created and tested in the lab. mRNA can be thought of as “biological software”, designed to encode executable instructions within human cells. Molecules that prove successful in the lab are licensed to pharmaceutical partners for clinical development.
Inceptive was founded in 2021 by Jakob Uszkoreit, formerly a Google AI researcher that worked on Google DeepMind's AlphaFold. Inceptive builds on generative AI technology pioneered by Uszkoreit and his colleagues. Uszkoreit is credited for the idea of focusing on attention, which was the basis for a publication on transformer models and laid the foundation for subsequent AI technology. Inceptive applies similar techniques to generate biological data instead of text or images.
Inceptive partnered with a major European pharmaceutical company to develop a new mRNA vaccine against infectious disease.
Funding from NVIDIA allowed Inceptive to have access to their computing platforms and chips.
September 7, 2023
Funding was led by NVIDIA's NVentures and Andreessen Horowitz.